CANCER FUND is excited to announce its impact investment in Veana Therapeutics, an early clinical-stage innovator developing a novel oral medication for breast cancer patients. Veana is CANCER FUND’s sixth investment out of Cancer Fund I, LLC and becomes our fifth portfolio company in our mission to support cancer innovation.
Veana’s oral medicine focuses on destabilizing mitochondria selectively in cancer cells while sparing normal cells, potentially offering effective treatment and improved quality of life for patients in treatment. Early clinical trials among women with intractable breast cancer have shown favorable results and a manageable safety profile and we are proud to be supporting expansion of trials to help their innovation on the path to patients.
“Helping the patients in Veana’s current and upcoming trials is at the top of our list of reasons we support Veana. The path to reaching human patients is incredibly long and full of challenges for teams like Veana developing these cancer innovations", said CANCER FUND Managing Director Anthony Bajoras. “We’re pleased to join the special group of new investors in the Seed Round - including Portfolia’s Active Aging and Longevity Fund II, The Alliance of Angels, and other previous investors.”
Veana’s CEO Patricia Beckmann, PhD, noted “Veana is honored to add Cancer Fund I as a new investor. We have been excited about their unique community-driven model, opening early investment opportunities to impact investors supporting cancer innovation, and by their investors’ and team members’ passion and professionalism.”
Learn more: https://lnkd.in/gngs2yVe
